Beijing Huafang Investment Co., founded in 2006, is a venture capital firm based in Beijing, China. The company specializes in the investment and management of state-owned capital, with a primary focus on commercial real estate. In addition to real estate, its investment portfolio includes sectors such as healthcare services and intangible cultural heritage, reflecting a commitment to diverse investment opportunities within the Chinese economy.
Fineimmu specializes in the development of innovative cell therapy drugs and immunodiagnostic products aimed at improving cancer treatment. The company's technology is centered on individualized tumor immunotherapy and immunodiagnostics, enabling healthcare professionals to assess the anti-tumor immune function of key proteins like PD-1 and PD-L1. Fineimmu's approach also includes precise combination therapies and rapid efficacy assessments, which together contribute to effective treatment systems for patients with common malignant tumors. The company aims to enhance therapeutic outcomes through personalized medicine, addressing the unique needs of each patient.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.